INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368394, 'Metronidazole', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368395, 'Tetracycline', 'Magaldrate', 'Moderate', 'INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368396, 'Tetracycline', 'Magnesium carbonate', 'Moderate', 'INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368397, 'Tetracycline', 'Magnesium chloride', 'Moderate', 'INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368398, 'Tetracycline', 'Magnesium citrate', 'Moderate', 'INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368399, 'Tetracycline', 'Magnesium gluconate', 'Moderate', 'INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368400, 'Tetracycline', 'Magnesium hydroxide', 'Moderate', 'INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368401, 'Tetracycline', 'Magnesium oxide', 'Moderate', 'INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368402, 'Tetracycline', 'Magnesium sulfate', 'Moderate', 'INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', NULL, 'The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368403, 'Metronidazole', 'Mebendazole', 'Moderate', 'Limited clinical data have suggested that coadministration of metronidazole and mebendazole may be associated with Stevens-Johnson syndrome/toxic epidermal necrolysis. The mechanism is unknown.', NULL, 'It is recommended that concomitant use of mebendazole and metronidazole should be avoided.', NULL, 'It is recommended that concomitant use of mebendazole and metronidazole should be avoided.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368404, 'Metronidazole', 'Methylphenobarbital', 'Moderate', 'Coadministration with a barbiturate may significantly decrease the plasma concentrations and pharmacologic effects of nitroimidazoles. The proposed mechanism is barbiturate induction of nitroimidazole metabolism via hepatic microsomal enzymes.', NULL, 'Patients treated concomitantly with a barbiturate may require a higher dosage of metronidazole to achieve a cure.', NULL, 'Patients treated concomitantly with a barbiturate may require a higher dosage of metronidazole to achieve a cure. Two- to threefold dosage increases are not uncommon. Pharmacologic response to metronidazole should be monitored and the dosage adjusted as necessary. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data are lacking.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368405, 'Tetracycline', 'Meticillin', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', NULL, 'This combination should be avoided if possible.', NULL, 'This combination should be avoided if possible.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368406, 'Tetracycline', 'Methotrexate', 'Moderate', 'Concomitant use of tetracyclines may elevate or reduce serum methotrexate concentrations. One mechanism may involve displacement of methotrexate from its binding to plasma proteins. Individual cases of methotrexate toxicity have been reported with doxycycline and tetracycline. In contrast, it has also been reported that oral antibiotics such as tetracyclines may reduce the intestinal absorption of methotrexate or interfere with its enterohepatic circulation or by inhibiting bowel flora and suppressing the metabolism of methotrexate by bacteria. However, the clinical significance of this effect has not been established.', NULL, 'If these drugs must be used together, close monitoring for evidence of serious methotrexate toxicity or reduced therapeutic efficacy is recommended.', NULL, 'If these drugs must be used together, close monitoring for evidence of serious methotrexate toxicity or reduced therapeutic efficacy is recommended. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, the use of an alternate anti-infective may be considered.', 'Absorption, Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368407, 'Tetracycline', 'Methoxsalen', 'Moderate', 'Concomitant use of methoxsalen with other known photosensitizing agents may increase the risk of photosensitivity reactions. These agents include anthralin, coal tar or coal tar derivatives, griseofulvin, hypericin extracts (e.g., St John''s Wort), fluoroquinolones, phenothiazines, retinoids, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, sulfonylureas, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal, and methyl orange.', NULL, 'Caution is advised and pharmacologic response to methoxsalen therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.', NULL, 'Caution is advised and pharmacologic response to methoxsalen therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid sun exposure, even through window glass or cloud cover, for at least 8 hours after methoxsalen ingestion and during the 24 hours following photochemotherapy or photopheresis treatment.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368408, 'Tetracycline', 'Methoxyflurane', 'Major', 'Coadministration of tetracycline or oxytetracycline with methoxyflurane has enhanced renal toxicity. The mechanism is not known.', NULL, 'This combination should be avoided if possible.', NULL, 'This combination should be avoided if possible.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368409, 'Tetracycline', 'Methylergometrine', 'Moderate', 'Limited data suggest that tetracyclines may increase the plasma concentrations and toxicity of ergot alkaloids. The mechanism is unknown, but may be related to tetracycline effects on liver function. Several cases of ergotism have been reported in patients taking ergotamine or dihydroergotamine with a tetracycline.', NULL, 'Caution may be advisable when ergot alkaloids are prescribed in combination with tetracyclines.', NULL, 'Caution may be advisable when ergot alkaloids are prescribed in combination with tetracyclines. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension. Patients should be advised to notify their physician if they experience potential signs and symptoms of ergotism such as paraesthesia, cyanosis, cold or painful extremities, muscle pain or weakness, abdominal pain, irregular heartbeat, and chest pain or tightness.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368410, 'Tetracycline', 'Methysergide', 'Moderate', 'Limited data suggest that tetracyclines may increase the plasma concentrations and toxicity of ergot alkaloids. The mechanism is unknown, but may be related to tetracycline effects on liver function. Several cases of ergotism have been reported in patients taking ergotamine or dihydroergotamine with a tetracycline.', NULL, 'Caution may be advisable when ergot alkaloids are prescribed in combination with tetracyclines.', NULL, 'Caution may be advisable when ergot alkaloids are prescribed in combination with tetracyclines. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension. Patients should be advised to notify their physician if they experience potential signs and symptoms of ergotism such as paraesthesia, cyanosis, cold or painful extremities, muscle pain or weakness, abdominal pain, irregular heartbeat, and chest pain or tightness.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368411, 'Tetracycline', 'Mezlocillin', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', NULL, 'This combination should be avoided if possible.', NULL, 'This combination should be avoided if possible.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368412, 'Bismuth subcitrate potassium', 'Minocycline', 'Moderate', 'INTERVAL: Administration of a bismuth-containing preparation within two to three hours of a tetracycline may significantly decrease serum tetracycline concentrations. Data are available for tetracycline and doxycycline. The proposed mechanism is chelation of tetracycline by bismuth.', NULL, 'Administration of a tetracycline and bismuth-containing preparation should be separated by two to three hours.', NULL, 'Administration of a tetracycline and bismuth-containing preparation should be separated by two to three hours. Patients should be monitored for diminished tetracycline efficacy.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368413, 'Tetracycline', 'Mipomersen', 'Major', 'Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.', NULL, 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.', NULL, 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368414, 'Tetracycline', 'Mivacurium', 'Moderate', 'Some drugs may enhance the effects of neuromuscular blocking agents.', NULL, 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', NULL, 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368415, 'Montelukast', 'Metronidazole', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 2C9 may increase the plasma concentrations of montelukast, which is metabolized by these isoenzymes in addition to CYP450 3A4. When montelukast was administered with the potent CYP450 2C8/2C9 inhibitor gemfibrozil, montelukast systemic exposure (AUC) increased by 4.4-fold.', NULL, 'According to the product labeling, no dosage adjustment of montelukast is required when used in combination with gemfibrozil.', NULL, 'According to the product labeling, no dosage adjustment of montelukast is required when used in combination with gemfibrozil. However, it may be advisable to monitor patients for potentially increased adverse effects during coadministration with gemfibrozil or other CYP450 2C8/2C9 inhibitors.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368416, 'Tetracycline', 'Mycophenolate mofetil', 'Moderate', 'Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.', NULL, 'Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.', NULL, 'Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368417, 'Tetracycline', 'Nafcillin', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', NULL, 'This combination should be avoided if possible.', NULL, 'This combination should be avoided if possible.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368418, 'Nateglinide', 'Metronidazole', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of nateglinide, which is primarily metabolized by the isoenzyme.', NULL, 'Because the antidiabetic effect of nateglinide is dose- and concentration-dependent, close monitoring for the development of hypoglycemia is recommended during coadministration with CYP450 2C9 inhibitors.', NULL, 'Because the antidiabetic effect of nateglinide is dose- and concentration-dependent, close monitoring for the development of hypoglycemia is recommended during coadministration with CYP450 2C9 inhibitors. Patients should regularly monitor their blood sugar and learn how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitation. The dosage of nateglinide may require adjustment if an interaction is suspected. Likewise, patients should be observed for potential loss of glycemic control following discontinuation of the CYP450 2C9 inhibitor, and the nateglinide dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368419, 'Nitrofurantoin', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368420, 'Tetracycline', 'Oxacillin', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', NULL, 'This combination should be avoided if possible.', NULL, 'This combination should be avoided if possible.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368421, 'Oxaliplatin', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368422, 'Tetracycline', 'Oxtriphylline', 'Moderate', 'Coadministration of a tetracycline may decrease theophylline plasma clearance and increase theophylline levels. Data are available for minocycline, tetracycline, and doxycycline, but are conflicting in some cases. This interaction appears to be more problematic if a tetracycline is administered for more than five days. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.', NULL, 'If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended.', NULL, 'If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended. Patients should be advised to notify their physician if they experience any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats. It may be necessary to reduce theophylline dosage.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368423, 'Tetracycline', 'Pancuronium', 'Moderate', 'Some drugs may enhance the effects of neuromuscular blocking agents.', NULL, 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', NULL, 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368424, 'Tetracycline', 'Pegaspargase', 'Moderate', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.', NULL, 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.', NULL, 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368425, 'Peginterferon alfa-2a', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368426, 'Peginterferon alfa-2b', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368427, 'Pentobarbital', 'Metronidazole', 'Moderate', 'Coadministration with a barbiturate may significantly decrease the plasma concentrations and pharmacologic effects of nitroimidazoles. The proposed mechanism is barbiturate induction of nitroimidazole metabolism via hepatic microsomal enzymes.', NULL, 'Patients treated concomitantly with a barbiturate may require a higher dosage of metronidazole to achieve a cure.', NULL, 'Patients treated concomitantly with a barbiturate may require a higher dosage of metronidazole to achieve a cure. Two- to threefold dosage increases are not uncommon. Pharmacologic response to metronidazole should be monitored and the dosage adjusted as necessary. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data are lacking.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368428, 'Tetracycline', 'Pexidartinib', 'Major', 'Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.', NULL, 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided.', NULL, 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368429, 'Phenytoin', 'Metronidazole', 'Moderate', 'Coadministration with a nitroimidazole may increase the serum concentrations of phenytoin. The interaction has been reported with metronidazole, and the proposed mechanism is inhibition of phenytoin metabolism via CYP450 2C9.', NULL, 'Pharmacologic response and serum phenytoin levels should be monitored more closely whenever metronidazole is added to or withdrawn from therapy, and the phenytoin (or fosphenytoin) dosage adjusted as necessary.', NULL, 'Pharmacologic response and serum phenytoin levels should be monitored more closely whenever metronidazole is added to or withdrawn from therapy, and the phenytoin (or fosphenytoin) dosage adjusted as necessary. Patients should be advised to notify their physician if they experience potential symptoms of phenytoin toxicity such as nausea, vomiting, nystagmus, slurred speech, lethargy, tremor, ataxia, hyperreflexia, and dysarthria. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data are lacking.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368430, 'Tetracycline', 'Piperacillin', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', NULL, 'This combination should be avoided if possible.', NULL, 'This combination should be avoided if possible.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368431, 'Tetracycline', 'Porfimer sodium', 'Moderate', 'Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.', NULL, 'Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient''s hepatic and/or renal function.', NULL, 'Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient''s hepatic and/or renal function.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368432, 'Tetracycline', 'Potassium citrate', 'Moderate', 'INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', 'Excretion', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368433, 'Pravastatin', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368434, 'Primidone', 'Metronidazole', 'Moderate', 'Coadministration with a barbiturate may significantly decrease the plasma concentrations and pharmacologic effects of nitroimidazoles. The proposed mechanism is barbiturate induction of nitroimidazole metabolism via hepatic microsomal enzymes.', NULL, 'Patients treated concomitantly with a barbiturate may require a higher dosage of metronidazole to achieve a cure.', NULL, 'Patients treated concomitantly with a barbiturate may require a higher dosage of metronidazole to achieve a cure. Two- to threefold dosage increases are not uncommon. Pharmacologic response to metronidazole should be monitored and the dosage adjusted as necessary. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data are lacking.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368435, 'Tetracycline', 'Quinapril', 'Moderate', 'INTERVAL: Administration of a tetracycline with quinapril may significantly decrease tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the magnesium excipient in quinapril.', NULL, 'The manufacturer does not make a specific recommendation, but generally the administration of tetracyclines and magnesium-containing products should be separated by two to four hours.', NULL, 'The manufacturer does not make a specific recommendation, but generally the administration of tetracyclines and magnesium-containing products should be separated by two to four hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368436, 'Tetracycline', 'Ranitidine (bismuth citrate)', 'Moderate', 'INTERVAL: Administration of a bismuth-containing preparation within two to three hours of a tetracycline may significantly decrease serum tetracycline concentrations. Data are available for tetracycline and doxycycline. The proposed mechanism is chelation of tetracycline by bismuth.', NULL, 'Administration of a tetracycline and bismuth-containing preparation should be separated by two to three hours.', NULL, 'Administration of a tetracycline and bismuth-containing preparation should be separated by two to three hours. Patients should be monitored for diminished tetracycline efficacy.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368437, 'Rifabutin', 'Metronidazole', 'Moderate', 'Coadministration with a rifamycin may decrease the plasma concentrations of nitroimidazoles. The proposed mechanism is rifamycin induction of nitroimidazole metabolism via hepatic microsomal enzymes.', NULL, 'Pharmacologic response to metronidazole should be monitored more closely during coadministration with a rifamycin, and the dosage adjusted as necessary.', NULL, 'Pharmacologic response to metronidazole should be monitored more closely during coadministration with a rifamycin, and the dosage adjusted as necessary. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data are lacking.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368438, 'Rifampicin', 'Metronidazole', 'Moderate', 'Coadministration with a rifamycin may decrease the plasma concentrations of nitroimidazoles. The proposed mechanism is rifamycin induction of nitroimidazole metabolism via hepatic microsomal enzymes.', NULL, 'Pharmacologic response to metronidazole should be monitored more closely during coadministration with a rifamycin, and the dosage adjusted as necessary.', NULL, 'Pharmacologic response to metronidazole should be monitored more closely during coadministration with a rifamycin, and the dosage adjusted as necessary. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data are lacking.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368439, 'Rifapentine', 'Metronidazole', 'Moderate', 'Coadministration with a rifamycin may decrease the plasma concentrations of nitroimidazoles. The proposed mechanism is rifamycin induction of nitroimidazole metabolism via hepatic microsomal enzymes.', NULL, 'Pharmacologic response to metronidazole should be monitored more closely during coadministration with a rifamycin, and the dosage adjusted as necessary.', NULL, 'Pharmacologic response to metronidazole should be monitored more closely during coadministration with a rifamycin, and the dosage adjusted as necessary. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data are lacking.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368440, 'Ritonavir', 'Metronidazole', 'Moderate', 'Ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, and tipranavir capsules all contain alcohol, which may produce a disulfiram-like reaction when coadministered with drugs that can inhibit aldehyde dehydrogenase (ALDH) such as nitroimidazoles (e.g., metronidazole, tinidazole), nitrofurans (e.g., furazolidone, nifurtimox), and cephalosporins with an N-methylthiotetrazole (NMTT) side chain that structurally resembles disulfiram. Following ingestion of alcohol, inhibition of ALDH results in increased concentrations of acetaldehyde, the accumulation of which can produce an unpleasant physiologic response referred to as the ''disulfiram reaction''. Symptoms include flushing, throbbing in head and neck, throbbing headache, respiratory difficulty, nausea, vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, tachycardia, hypotension, syncope, weakness, vertigo, blurred vision, and confusion. Severe reactions may result in respiratory depression, cardiovascular collapse, arrhythmia, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death. The interaction is well established for disulfiram.', NULL, 'Until further information is available, use of ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, or tipranavir capsules with nitroimidazoles (including vaginal formulations), nitrofurans, and certain cephalosporins should be avoided if possible.', NULL, 'Until further information is available, use of ritonavir capsules, ritonavir oral solution, lopinavir-ritonavir oral solution, or tipranavir capsules with nitroimidazoles (including vaginal formulations), nitrofurans, and certain cephalosporins should be avoided if possible.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368441, 'Rivastigmine', 'Metronidazole', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368442, 'Tetracycline', 'Rocuronium', 'Moderate', 'Some drugs may enhance the effects of neuromuscular blocking agents.', NULL, 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', NULL, 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368443, 'Rosuvastatin', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368444, 'Secobarbital', 'Metronidazole', 'Moderate', 'Coadministration with a barbiturate may significantly decrease the plasma concentrations and pharmacologic effects of nitroimidazoles. The proposed mechanism is barbiturate induction of nitroimidazole metabolism via hepatic microsomal enzymes.', NULL, 'Patients treated concomitantly with a barbiturate may require a higher dosage of metronidazole to achieve a cure.', NULL, 'Patients treated concomitantly with a barbiturate may require a higher dosage of metronidazole to achieve a cure. Two- to threefold dosage increases are not uncommon. Pharmacologic response to metronidazole should be monitored and the dosage adjusted as necessary. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data are lacking.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368445, 'Simvastatin', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368446, 'Tetracycline', 'Sodium acetate', 'Moderate', 'INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', 'Excretion', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368447, 'Tetracycline', 'Sodium bicarbonate', 'Moderate', 'INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', 'Excretion', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368448, 'Iodide I-131', 'Metronidazole', 'Moderate', 'INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.', NULL, 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.', NULL, 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368449, 'Tetracycline', 'Lactic acid', 'Moderate', 'INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', 'Excretion', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368450, 'Stavudine', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368451, 'Tetracycline', 'Succinylcholine', 'Moderate', 'Some drugs may enhance the effects of neuromuscular blocking agents.', NULL, 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', NULL, 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368452, 'Tetracycline', 'Sucralfate', 'Moderate', 'INTERVAL: Simultaneous administration of sucralfate may interfere with the absorption of tetracyclines and reduce their oral bioavailability. Sucralfate is an aluminum salt of a sulfated disaccharide. The aluminum moiety can dissociate at gastric pH and chelate with tetracyclines to form an insoluble complex that is poorly absorbed from the gastrointestinal tract. Reduced antibiotic efficacy may occur.', NULL, 'To minimize the potential for interaction, tetracyclines should be administered at least 2 hours before sucralfate.', NULL, 'To minimize the potential for interaction, tetracyclines should be administered at least 2 hours before sucralfate.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368453, 'Tacrine', 'Metronidazole', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368454, 'Tacrolimus', 'Metronidazole', 'Moderate', 'Coadministration with a nitroimidazole may increase the blood concentrations of tacrolimus. The interaction has been reported with metronidazole, and the proposed mechanism is inhibition of hepatic tacrolimus metabolism via CYP450 3A4.', NULL, 'Caution is advised if tacrolimus is used with metronidazole.', NULL, 'Caution is advised if tacrolimus is used with metronidazole. Tacrolimus blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of metronidazole therapy in patients who are stabilized on their tacrolimus regimen. Given its structural similarities to metronidazole, the same precaution may be applicable during therapy with tinidazole, although clinical data are lacking.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368455, 'Teniposide', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368456, 'Thalidomide', 'Metronidazole', 'Moderate', 'Thalidomide can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Peripheral neuropathy is a common, potentially severe side effect of thalidomide that may be irreversible.', NULL, 'Caution is advised if thalidomide is used in combination with other neurotoxic agents.', NULL, 'Caution is advised if thalidomide is used in combination with other neurotoxic agents. All patients treated with thalidomide should be examined at monthly intervals for the first three months of therapy and periodically thereafter to detect early signs of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Electrophysiological testing may be performed at baseline and every six months during therapy to detect asymptomatic neuropathy. Consideration should be given to immediate discontinuation of thalidomide in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368457, 'Theophylline', 'Tetracycline', 'Moderate', 'Coadministration of a tetracycline may decrease theophylline plasma clearance and increase theophylline levels. Data are available for minocycline, tetracycline, and doxycycline, but are conflicting in some cases. This interaction appears to be more problematic if a tetracycline is administered for more than five days. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.', NULL, 'If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended.', NULL, 'If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended. Patients should be advised to notify their physician if they experience any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or irregular heartbeats. It may be necessary to reduce theophylline dosage.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368458, 'Ticarcillin', 'Tetracycline', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', NULL, 'This combination should be avoided if possible.', NULL, 'This combination should be avoided if possible.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368459, 'Torasemide', 'Metronidazole', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of torsemide. The interaction has not been evaluated in pharmacokinetic studies; however, torsemide has been shown to undergo metabolism by CYP450 2C9.', NULL, 'Caution is advised when torsemide is prescribed with CYP450 2C9 inhibitors.', NULL, 'Caution is advised when torsemide is prescribed with CYP450 2C9 inhibitors. Patients should be monitored for potentially increased adverse effects such as dehydration, hypotension, electrolyte imbalances, hyperglycemia, tinnitus, and hearing loss.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368460, 'Tretinoin', 'Tetracycline', 'Major', 'Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign intracranial hypertension. These agents individually have been associated with the development of pseudotumor cerebri and may have additive effects during coadministration. The interaction has been suspected in reported cases involving the use of isotretinoin or vitamin A in combination with a tetracycline.', NULL, 'Coadministration of most retinoids with tetracyclines is considered contraindicated.', NULL, 'Coadministration of most retinoids with tetracyclines is considered contraindicated. Patients treated with a retinoid or a tetracycline should be advised to discontinue the medication and notify their physician immediately if they develop early symptoms of pseudotumor cerebri such as headache, nausea, vomiting, visual disturbances, vision loss, and papilledema. Although intracranial hypertension typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. Therefore, prompt ophthalmologic evaluation should be performed if visual disturbances occur. Since intracranial pressure may remain elevated for weeks after drug cessation, patients should be monitored until they stabilize.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368461, 'Tromethamine', 'Tetracycline', 'Moderate', 'INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', NULL, 'If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).', 'Excretion', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368462, 'Typhoid vaccine (live)', 'Metronidazole', 'Major', 'INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.', NULL, 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.', NULL, 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368463, 'Valdecoxib', 'Metronidazole', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 and/or 3A4 may increase the plasma concentrations of valdecoxib, which is metabolized by these isoenzymes.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of valdecoxib or parecoxib, including serious adverse effects such as gastrointestinal ulceration and bleeding, should be considered during concomitant therapy with CYP450 2C9 or 3A4 inhibitors, particularly combination (2C9/3A4) inhibitors such as fluconazole, fluvoxamine, imatinib, and zafirlukast.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of valdecoxib or parecoxib, including serious adverse effects such as gastrointestinal ulceration and bleeding, should be considered during concomitant therapy with CYP450 2C9 or 3A4 inhibitors, particularly combination (2C9/3A4) inhibitors such as fluconazole, fluvoxamine, imatinib, and zafirlukast. Dose reductions of the COX-2 inhibitor may be required.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368464, 'Vardenafil', 'Metronidazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations of vardenafil, which is primarily metabolized by the former and secondarily by the latter. The possibility of prolonged and/or increased pharmacologic effects of vardenafil should be considered.', NULL, 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance.', NULL, 'Dosage adjustments may be appropriate for vardenafil whenever a CYP450 3A4 and/or 2C9 inhibitor is added to or withdrawn from therapy based on efficacy and patient tolerance. The manufacturer recommends that an initial vardenafil dosage of 2.5 to 5 mg be used in patients treated concomitantly with a potent CYP450 3A4 inhibitor such as erythromycin, itraconazole, ketoconazole, indinavir, and ritonavir.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368465, 'Vecuronium', 'Tetracycline', 'Moderate', 'Some drugs may enhance the effects of neuromuscular blocking agents.', NULL, 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', NULL, 'Observation for profound and prolonged respiratory depression and muscle weakness is recommended if these drugs must be used together.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368466, 'Verteporfin', 'Tetracycline', 'Moderate', 'Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John''s Wort).', NULL, 'Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.', NULL, 'Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368467, 'Vinblastine', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368468, 'Vincristine', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368469, 'Vinorelbine', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368470, 'Vitamin A', 'Tetracycline', 'Major', 'Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign intracranial hypertension. These agents individually have been associated with the development of pseudotumor cerebri and may have additive effects during coadministration. Both acute and chronic vitamin A intoxication have been identified as secondary causes of pseudotumor cerebri.', NULL, 'Caution is advised if vitamin A is coadministered with tetracyclines.', NULL, 'Caution is advised if vitamin A is coadministered with tetracyclines. Concomitant use of most retinoids with tetracyclines is considered contraindicated. Patients treated with any of these agents should be advised to discontinue treatment and notify their physician immediately if they develop early symptoms of pseudotumor cerebri such as headache, nausea, vomiting, visual disturbances, vision loss, and papilledema. Although intracranial hypertension typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. Therefore, prompt ophthalmologic evaluation should be performed if visual disturbances occur. Since intracranial pressure may remain elevated for weeks after drug cessation, patients should be monitored until they stabilize.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368471, 'Warfarin', 'Metronidazole', 'Major', 'Coadministration with metronidazole may increase the plasma concentrations and hypoprothrombinemic effect of warfarin. The proposed mechanism is metronidazole inhibition of CYP450 2C9, the isoenzyme responsible for the metabolic clearance of the more active S(-) enantiomer of warfarin.', NULL, 'Given the potential for interaction and the high degree of interpatient variability with respect to warfarin metabolism, patients should be closely monitored during concomitant therapy with metronidazole.', NULL, 'Given the potential for interaction and the high degree of interpatient variability with respect to warfarin metabolism, patients should be closely monitored during concomitant therapy with metronidazole. The INR should be checked frequently and warfarin dosage adjusted accordingly, particularly following initiation or discontinuation of metronidazole in patients who are stabilized on their warfarin regimen. The same precaution may be applicable during therapy with other oral anticoagulants, although clinical data are lacking. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368472, 'Zafirlukast', 'Metronidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368473, 'Zalcitabine', 'Metronidazole', 'Moderate', 'Zalcitabine can cause peripheral neuropathy in up to one-third of patients with advanced HIV disease, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Zalcitabine-related peripheral neuropathy is a sensorimotor neuropathy characterized initially by numbness and burning dysesthesia involving the distal extremities. These symptoms may be followed by sharp shooting pains or severe continuous burning pain if the drug is not withdrawn, and progress to severe pain requiring narcotic analgesics. The neuropathy is potentially irreversible. However, with prompt discontinuation of zalcitabine, it is usually slowly reversible, although symptoms may initially progress following discontinuation.', NULL, 'Use of zalcitabine with other drugs that have the potential to cause peripheral neuropathy should be avoided whenever possible.', NULL, 'Use of zalcitabine with other drugs that have the potential to cause peripheral neuropathy should be avoided whenever possible. Otherwise, careful monitoring is recommended for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness in the extremities, particularly in patients with a low CD4 cell count or diabetes. Since the development of peripheral neuropathy appears to be dose-related, the recommended dosage of zalcitabine should not be exceeded. Patients should be advised to promptly discontinue zalcitabine therapy and contact their physician if neuropathy develops. Therapy may be reinstituted following resolution of neuropathy symptoms, but dosage should be reduced to one-half the initially recommended dosage. Zalcitabine should be permanently discontinued in patients who develop severe peripheral neuropathy during treatment.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368474, 'Zinc acetate', 'Tetracycline', 'Moderate', 'INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.', NULL, 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368475, 'Zinc chloride', 'Tetracycline', 'Moderate', 'INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.', NULL, 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368476, 'Zinc gluconate', 'Tetracycline', 'Moderate', 'INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.', NULL, 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368477, 'Zinc sulfate', 'Tetracycline', 'Moderate', 'INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', NULL, 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.', NULL, 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368478, 'Bisoprolol', 'Acetohexamide', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368479, 'Aluminum hydroxide', 'Bisoprolol', 'Minor', 'Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368480, 'Aminophylline', 'Bisoprolol', 'Major', 'The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.', NULL, 'Oral and ophthalmic nonselective beta-blockers (e.', NULL, 'Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368481, 'Amoxapine', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368482, 'Bisoprolol', 'Arbutamine', 'Moderate', 'Beta-blockers will attenuate the desired effects of arbutamine.', NULL, 'Beta-blockers should be discontinued at least 48 hours before arbutamine is administered.', NULL, 'Beta-blockers should be discontinued at least 48 hours before arbutamine is administered.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368483, 'Bisoprolol', 'Atracurium', 'Moderate', 'Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368484, 'Bisoprolol', 'Attapulgite', 'Minor', 'Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368485, 'Bisoprolol', 'Belladonna', 'Moderate', 'Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', 'Synergism, Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368486, 'Bisoprolol', 'Bendroflumethiazide', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368487, 'Bisoprolol', 'Benzthiazide', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368488, 'Bisoprolol', 'Bepridil', 'Moderate', 'Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'Metabolism, Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368489, 'Brexpiprazole', 'Bisoprolol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368490, 'Brigatinib', 'Bisoprolol', 'Moderate', 'Coadministration of brigatinib with other agents that can also slow the heart rate may potentiate the risk of severe bradycardia.', NULL, 'Caution is advised if brigatinib is used concomitantly with beta-blockers, calcium channel blockers, digitalis, or other drugs that can slow the heart rate or atrioventricular conduction such as alectinib, atazanavir, fingolimod, flecainide, ivabradine, lacosamide, lithium, mefloquine, moricizine, propafenone, succinylcholine, thalidomide, H2-receptor antagonists, tricyclic antidepressants, and anticholinesterase or cholinergic agents.', NULL, 'Caution is advised if brigatinib is used concomitantly with beta-blockers, calcium channel blockers, digitalis, or other drugs that can slow the heart rate or atrioventricular conduction such as alectinib, atazanavir, fingolimod, flecainide, ivabradine, lacosamide, lithium, mefloquine, moricizine, propafenone, succinylcholine, thalidomide, H2-receptor antagonists, tricyclic antidepressants, and anticholinesterase or cholinergic agents. Heart rate and blood pressure should be monitored frequently, and patients should be advised to seek medical attention if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368491, 'Brimonidine (ophthalmic)', 'Bisoprolol', 'Moderate', 'Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects such as hypotension and bradycardia. The possibility for an additive or potentiating effect on blood pressure and heart rate should be considered when used with other medications that affect these parameters, such as ophthalmic and systemic beta blockers, vasodilators, cardiac glycosides, and antihypertensive agents.', NULL, 'Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs.', NULL, 'Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs. Patients should be advised to notify their physician if they experience slow pulse, irregular heartbeat, dizziness, lightheadedness, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368492, 'Brimonidine (topical)', 'Bisoprolol', 'Moderate', 'Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects such as hypotension and bradycardia. The possibility for an additive or potentiating effect on blood pressure and heart rate should be considered when used with other medications that affect these parameters, such as ophthalmic and systemic beta blockers, vasodilators, cardiac glycosides, and antihypertensive agents.', NULL, 'Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs.', NULL, 'Blood pressure and pulse rate should be monitored regularly when topical alpha-2 adrenergic receptor agonists are prescribed in combination with cardiovascular drugs. Patients should be advised to notify their physician if they experience slow pulse, irregular heartbeat, dizziness, lightheadedness, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368493, 'Bromfenac', 'Bisoprolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368494, 'Bromocriptine', 'Bisoprolol', 'Moderate', 'Several case reports have suggested that beta-blockers may potentiate the vasoconstrictive action of ergot alkaloids. The exact mechanism of interaction is unknown, but may involve blockade of beta-2-mediated (i.e., sympathetic) vasodilatation. In addition, beta-1 blockade reduces cardiac output, which can diminish blood flow and exacerbate ergot-induced vasospasm.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary. Patients should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368495, 'Budesonide', 'Bisoprolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368496, 'Bumetanide', 'Bisoprolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368497, 'Bupivacaine', 'Bisoprolol', 'Moderate', 'Beta-blockers may increase the risk of bupivacaine-induced side effects. The proposed mechanism is increased bupivacaine levels due to hepatic enzyme inhibition (propranolol) and/or additive negative inotropic effects on the heart.', NULL, 'Caution is recommended if multiple doses of bupivacaine are administered in the presence of a beta-blocker.', NULL, 'Caution is recommended if multiple doses of bupivacaine are administered in the presence of a beta-blocker. Monitoring for drowsiness, mental status changes, convulsions, ECG changes, and hypotension is advisable during concurrent therapy.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368498, 'Buprenorphine', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368499, 'Buspirone', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368500, 'Butabarbital', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368501, 'Butorphanol', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368502, 'Cabergoline', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368503, 'Calcium acetate', 'Bisoprolol', 'Moderate', 'INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368504, 'Calcium carbonate', 'Bisoprolol', 'Moderate', 'INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368505, 'Calcium citrate', 'Bisoprolol', 'Moderate', 'INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368506, 'Calcium glubionate anhydrous', 'Bisoprolol', 'Moderate', 'INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368507, 'Calcium gluconate', 'Bisoprolol', 'Moderate', 'INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368508, 'Calcium lactate', 'Bisoprolol', 'Moderate', 'INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368509, 'Calcium Phosphate', 'Bisoprolol', 'Moderate', 'INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.', NULL, 'It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368510, 'Canagliflozin', 'Bisoprolol', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368511, 'Cariprazine', 'Bisoprolol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368512, 'Carisoprodol', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368513, 'Carteolol (ophthalmic)', 'Bisoprolol', 'Moderate', 'Ophthalmic beta blocker solutions are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Additive effects of beta blockade may occur in patients receiving both oral and ophthalmic beta blocking agents.', NULL, 'Blood pressure and intraocular pressure monitoring is recommended during concurrent use.', NULL, 'Blood pressure and intraocular pressure monitoring is recommended during concurrent use. Patients should be advised to notify their physician if they experience a slow pulse, irregular heartbeat, dizziness, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368514, 'Ceritinib', 'Bisoprolol', 'Major', 'Coadministration of ceritinib with other drugs that can slow the heart rate such as beta-blockers, calcium channel blockers, digitalis, and clonidine may increase the risk of bradycardia, which can lead to heart block and QT prolongation.', NULL, 'Concomitant use of ceritinib with other agents known to cause bradycardia should be avoided if possible.', NULL, 'Concomitant use of ceritinib with other agents known to cause bradycardia should be avoided if possible. All patients treated with ceritinib should have their heart rate and blood pressure monitored regularly. Consult the product labeling for dosage adjustment and management recommendations if symptomatic or life-threatening bradycardia occurs. Patients should be advised to notify their doctor if they experience irregular heartbeat, slow pulse, dizziness, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368515, 'Cevimeline', 'Bisoprolol', 'Moderate', 'Cevimeline may increase the risk of conduction abnormalities when administered with beta-blockers. The decrease in sinus node and AV conduction noted when these agents are used alone theoretically may be enhanced when used concurrently.', NULL, 'Cautious administration of cevimeline with a beta blocker and clinical monitoring of patient response and tolerance are recommended.', NULL, 'Cautious administration of cevimeline with a beta blocker and clinical monitoring of patient response and tolerance are recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368516, 'Chloral hydrate', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368517, 'Chlordiazepoxide', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368518, 'Chlormezanone', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368519, 'Chlorothiazide', 'Bisoprolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368520, 'Chlorphenesin', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368521, 'Chlorpromazine', 'Bisoprolol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368522, 'Chlorpropamide', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368523, 'Chlorthalidone', 'Bisoprolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368524, 'Chlorzoxazone', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368525, 'Choline salicylate', 'Bisoprolol', 'Minor', 'High doses of salicylates may blunt the antihypertensive effects of beta-blockers. The proposed mechanism is inhibition of prostaglandin synthesis. Low-dose aspirin does not appear to affect blood pressure. In addition, beta-blockers may exert an antiplatelet effect, which may be additive with the effects of some salicylates. Metoprolol may also increase aspirin absorption and/or plasma concentrations of salicylates; however, the clinical significance of this effect is unknown. Data have been conflicting. Until more information is available, patients who require concomitant therapy should be monitored for altered antihypertensive response whenever a salicylate is introduced or discontinued, or when its dosage is modified.', NULL, '-', NULL, '-', 'Antagonism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368526, 'Cimetidine', 'Bisoprolol', 'Moderate', 'H2 antagonists such as cimetidine increase plasma concentrations of some oral beta-blockers. The mechanism may be related to inhibition of CYP450 metabolism of hepatically metabolized beta-blockers, and/or inhibition of renal tubular secretion of others.', NULL, 'Clinical monitoring of patient response and tolerance is recommended when cimetidine is added to or discontinued from a beta-blocker regimen.', NULL, 'Clinical monitoring of patient response and tolerance is recommended when cimetidine is added to or discontinued from a beta-blocker regimen.', 'Metabolism, Excretion', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368527, 'Cisatracurium', 'Bisoprolol', 'Moderate', 'Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368528, 'Clevidipine', 'Bisoprolol', 'Moderate', 'Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'Metabolism, Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368529, 'Clidinium', 'Bisoprolol', 'Moderate', 'Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', 'Synergism, Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368530, 'Clobazam', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368531, 'Clomipramine', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368532, 'Clonazepam', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368533, 'Clonidine', 'Bisoprolol', 'Major', 'Clonidine and beta-blockers may have synergistic pharmacodynamic effects resulting in marked AV block, bradycardia, and hypotension. Conversely, cases of antagonism of hypotensive effects have been reported, the mechanism of which is unknown. In addition, potentiation of the hypertensive rebound associated with abrupt withdrawal of clonidine or both clonidine and the beta blocker may occur.', NULL, 'Close monitoring of blood pressure is recommended for patients receiving this combination.', NULL, 'Close monitoring of blood pressure is recommended for patients receiving this combination. Patients should be advised to notify their doctor if they experience a reduced heart rate, dizziness, fainting, or headaches. Clonidine should never be discontinued abruptly, but should be tapered off over 2 to 4 days. The beta blocker should be discontinued a few days before gradually discontinuing the clonidine. It has also been suggested that replacing clonidine and the beta blocker with labetalol (an alpha and beta blocker) may prevent rebound hypertension although some symptoms from increased catecholamine levels occur, or selecting a cardioselective beta blocker (e.g. atenolol, betaxolol, bisoprolol, metoprolol) which is theoretically not expected to exacerbate the pressor response. Patients being withdrawn from clonidine should be carefully monitored for blood pressure changes, severe headache, tremors, apprehension, flushing, nausea, and vomiting.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368534, 'Clorazepic acid', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368535, 'Clozapine', 'Bisoprolol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368536, 'Corticotropin', 'Bisoprolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368537, 'Bisoprolol', 'Tetracosactide', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368538, 'Crizotinib', 'Bisoprolol', 'Moderate', 'Crizotinib can cause bradycardia and may have additive effects with other drugs that also slow the heart rate.', NULL, 'Concomitant use of crizotinib with other agents known to cause bradycardia such as beta-blockers, calcium channel blockers, cholinesterase inhibitors, clonidine, and digoxin should generally be avoided whenever possible.', NULL, 'Concomitant use of crizotinib with other agents known to cause bradycardia such as beta-blockers, calcium channel blockers, cholinesterase inhibitors, clonidine, and digoxin should generally be avoided whenever possible. Otherwise, heart rate and blood pressure should be monitored closely. If Grade 2 or 3 symptomatic bradycardia occurs, crizotinib should be withheld, the use of concomitant medications re-evaluated, and the dosage of crizotinib adjusted accordingly. Crizotinib should be permanently discontinued for Grade 4 bradycardia. In patients who develop Grade 4 bradycardia associated with concomitant medications known to cause bradycardia or hypotension, crizotinib should be withheld until Grade 1 or less, and if concomitant medications can be discontinued, crizotinib may be restarted at 250 mg once daily with frequent monitoring.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368539, 'Cyclobenzaprine', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368540, 'Dapagliflozin', 'Bisoprolol', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368541, 'Deflazacort', 'Bisoprolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368542, 'Desipramine', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368543, 'Dexmedetomidine', 'Bisoprolol', 'Moderate', 'Dexmedetomidine has been associated with hypotensive and negative chronotropic effects. Coadministration with other agents causing these effects, especially vasodilators and alpha-2 agonists, may result in additive effects on blood pressure and heart rate.', NULL, 'Caution and monitoring of the patient''s hemodynamic status are recommended during coadministration.', NULL, 'Caution and monitoring of the patient''s hemodynamic status are recommended during coadministration.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368544, 'Diatrizoate', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368545, 'Diazepam', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368546, 'Diclofenac', 'Bisoprolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368547, 'Dicyclomine', 'Bisoprolol', 'Moderate', 'Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', 'Synergism, Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368548, 'Diflunisal', 'Bisoprolol', 'Minor', 'High doses of salicylates may blunt the antihypertensive effects of beta-blockers. The proposed mechanism is inhibition of prostaglandin synthesis. Low-dose aspirin does not appear to affect blood pressure. In addition, beta-blockers may exert an antiplatelet effect, which may be additive with the effects of some salicylates. Metoprolol may also increase aspirin absorption and/or plasma concentrations of salicylates; however, the clinical significance of this effect is unknown. Data have been conflicting. Until more information is available, patients who require concomitant therapy should be monitored for altered antihypertensive response whenever a salicylate is introduced or discontinued, or when its dosage is modified.', NULL, '-', NULL, '-', 'Antagonism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368549, 'Digitoxin', 'Bisoprolol', 'Moderate', 'Concomitant use of digitalis glycosides and beta-blockers may increase the risk of bradycardia. These agents slow atrioventricular conduction and decrease heart rate, hence they may have additive cardiac effects during coadministration. Some beta-blockers such as carvedilol, esmolol, and talinolol have also been reported to increase the systemic bioavailability of digoxin. The mechanism may involve enhanced absorption as well as reduced renal excretion of digoxin due to inhibition of intestinal and renal P-glycoprotein efflux transporter.', NULL, 'Caution is advised during coadministration of digitalis glycosides and beta-blockers.', NULL, 'Caution is advised during coadministration of digitalis glycosides and beta-blockers. Serum digitalis levels, heart rate, and blood pressure should be monitored closely, particularly during the first few weeks of concomitant therapy. Patients should be advised to notify their physician if they experience anorexia, nausea, visual changes, irregular heartbeat, slow pulse, dizziness, or syncope. Beta-blockers should not be used in patients with overt or decompensated congestive heart failure, as sympathetic stimulation may be a vital component in maintaining hemodynamic function in these patients and its inhibition by beta blockade may worsen the heart failure.', 'Excretion', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368550, 'Digoxin', 'Bisoprolol', 'Moderate', 'Concomitant use of digitalis glycosides and beta-blockers may increase the risk of bradycardia. These agents slow atrioventricular conduction and decrease heart rate, hence they may have additive cardiac effects during coadministration. Some beta-blockers such as carvedilol, esmolol, and talinolol have also been reported to increase the systemic bioavailability of digoxin. The mechanism may involve enhanced absorption as well as reduced renal excretion of digoxin due to inhibition of intestinal and renal P-glycoprotein efflux transporter.', NULL, 'Caution is advised during coadministration of digitalis glycosides and beta-blockers.', NULL, 'Caution is advised during coadministration of digitalis glycosides and beta-blockers. Serum digitalis levels, heart rate, and blood pressure should be monitored closely, particularly during the first few weeks of concomitant therapy. Patients should be advised to notify their physician if they experience anorexia, nausea, visual changes, irregular heartbeat, slow pulse, dizziness, or syncope. Beta-blockers should not be used in patients with overt or decompensated congestive heart failure, as sympathetic stimulation may be a vital component in maintaining hemodynamic function in these patients and its inhibition by beta blockade may worsen the heart failure.', 'Excretion', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368551, 'Dihydroergotamine', 'Bisoprolol', 'Moderate', 'Several case reports have suggested that beta-blockers may potentiate the vasoconstrictive action of ergot alkaloids. The exact mechanism of interaction is unknown, but may involve blockade of beta-2-mediated (i.e., sympathetic) vasodilatation. In addition, beta-1 blockade reduces cardiac output, which can diminish blood flow and exacerbate ergot-induced vasospasm.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary. Patients should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368552, 'Diltiazem', 'Bisoprolol', 'Major', 'Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers, especially verapamil and diltiazem, are used concomitantly with beta blockers. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. Ventricular asystole, sinus arrest, and heart block have also been reported.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if these agents are used together, and the dosage of one or both agents adjusted as necessary.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if these agents are used together, and the dosage of one or both agents adjusted as necessary. Patients should be advised to promptly report any symptoms including fatigue, headache, fainting, swelling of the extremities, weight gain, shortness of breath, chest pain, increased or decreased heartbeat, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368553, 'Dimenhydrinate', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368554, 'Diphenhydramine', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368555, 'Disopyramide', 'Bisoprolol', 'Major', 'Due to its potent negative inotropic and chronotropic effects, disopyramide has been associated with severe hypotension, syncope, severe bradycardia, asystole, and heart failure when used with beta-blockers. In addition, QT interval prolongation and excessive QRS complex widening may occur with concurrent administration of disopyramide and beta-blockers in the treatment of arrhythmias. The use of disopyramide has been associated with rare cases of significant hypoglycemia. Since beta-blockers may inhibit some of the normal physiologic response to hypoglycemia, glucoregulatory mechanisms (in the absence of food) may be compromised.', NULL, 'The use of disopyramide in combination with beta-blockers should generally be avoided unless the benefits are anticipated to outweigh the risks.', NULL, 'The use of disopyramide in combination with beta-blockers should generally be avoided unless the benefits are anticipated to outweigh the risks. Close monitoring of cardiac output, blood pressure, heart rate, and/or ECG is recommended if these drugs must be used together. Patients should be advised to seek medical attention if they experience dizziness, lightheadedness, syncope, palpitations, slow or fast pulse, or irregular heartbeats.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368556, 'Dobutamine', 'Bisoprolol', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.', NULL, 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368557, 'Dolasetron', 'Bisoprolol', 'Major', 'Dolasetron has been shown to cause dose-dependent prolongation of the PR and QRS intervals. There have been reports of second- and third-degree atrioventricular block, cardiac arrest, and serious ventricular arrhythmias including fatalities in both adult and pediatric patients.', NULL, 'Caution is advised if dolasetron is used concomitantly with other agents that prolong the PR or QRS interval, especially in the elderly and patients with known risk factors.', NULL, 'Caution is advised if dolasetron is used concomitantly with other agents that prolong the PR or QRS interval, especially in the elderly and patients with known risk factors. An ECG should be obtained in these patients before initiating dolasetron and periodically during treatment. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat. Dolasetron should be avoided in patients with complete heart block or at risk for complete heart block, unless they have an implanted pacemaker.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368558, 'Donepezil', 'Bisoprolol', 'Moderate', 'Since acetylcholinesterase inhibitors can cause bradycardia and heart block due to vagotonic effects on the sinoatrial and atrioventricular nodes, additive effects may occur with other agents that also possess bradycardic effects such as beta-blockers, calcium channel blockers, digitalis, some protease inhibitors (atazanavir, lopinavir-ritonavir, saquinavir), amiodarone, dronedarone, moricizine, lacosamide, and mefloquine.', NULL, 'Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs.', NULL, 'Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs. Patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368559, 'Dopamine', 'Bisoprolol', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.', NULL, 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368560, 'Doxacurium', 'Bisoprolol', 'Moderate', 'Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368561, 'Doxazosin', 'Bisoprolol', 'Moderate', 'Additive hypotensive effects may occur when beta-blockers are used in combination with alpha-blockers. In the presence of beta-blockade, the risk and/or severity of first-dose effects associated with alpha-blockers such as postural hypotension and syncope may be increased. Beta-blockers may also blunt the reflex tachycardia that occurs in response to postural hypotension. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations.', NULL, 'Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations. Small initial dosages of the alpha-blocker should be considered and gradually titrated to desired effect, while the systemic beta-blocker dosage may also need to be reduced. Hemodynamic responses should be monitored, especially during the first few weeks of therapy. Taking the alpha-blocker at bedtime may minimize the occurrence of orthostatic effects. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368562, 'Doxepin', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368563, 'Doxepin (topical)', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368564, 'Dronabinol', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368565, 'Dronedarone', 'Bisoprolol', 'Moderate', 'Coadministration with dronedarone may increase the plasma concentrations of some beta-blockers. The mechanism is dronedarone inhibition of CYP450 2D6, the isoenzyme responsible for the metabolic clearance of beta-blockers like metoprolol and propranolol. Pharmacodynamically, beta-blockers can potentiate the depressant effects of dronedarone on the sinus and AV nodes.', NULL, 'Caution is advised if dronedarone is coadministered with a beta-blocker, including ophthalmic formulations.', NULL, 'Caution is advised if dronedarone is coadministered with a beta-blocker, including ophthalmic formulations. The dosage of the beta-blocker should start low and increased only after ECG verification of good tolerability. Patients should be advised to promptly report potential symptoms of toxicity such as excessive fatigue, fainting, difficulty breathing, chest pain or tightness, bradycardia, or arrhythmia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368566, 'Dyphylline', 'Bisoprolol', 'Major', 'The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.', NULL, 'Oral and ophthalmic nonselective beta-blockers (e.', NULL, 'Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368567, 'Empagliflozin', 'Bisoprolol', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368568, 'Ephedrine', 'Bisoprolol', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of ephedrine by blocking beta-1 adrenergic receptors in the heart. Noncardioselective beta-blockers can antagonize the bronchodilating effects of ephedrine by blocking beta-2 adrenergic receptors in smooth muscles of the bronchial tree. The interaction is less likely to occur with cardioselective beta-blockers, which generally have little effect on beta-2 adrenergic receptors at therapeutic dosages.', NULL, 'Clinicians should be alert to the potential for diminished cardiac response when parenteral ephedrine is used in patients treated with beta-blockers, including ophthalmic formulations.', NULL, 'Clinicians should be alert to the potential for diminished cardiac response when parenteral ephedrine is used in patients treated with beta-blockers, including ophthalmic formulations. Noncardioselective beta-blockers, including ophthalmic formulations, should generally be avoided in patients using ephedrine-containing preparations for bronchospastic diseases. If beta-blocker therapy is necessary, an agent with beta-1 selectivity (e.g., atenolol, metoprolol, betaxolol) is considered safer. However, caution is advised, especially with higher dosages of the beta-blocker.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368569, 'Epoprostenol', 'Bisoprolol', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368570, 'Ergometrine', 'Bisoprolol', 'Moderate', 'Several case reports have suggested that beta-blockers may potentiate the vasoconstrictive action of ergot alkaloids. The exact mechanism of interaction is unknown, but may involve blockade of beta-2-mediated (i.e., sympathetic) vasodilatation. In addition, beta-1 blockade reduces cardiac output, which can diminish blood flow and exacerbate ergot-induced vasospasm.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary. Patients should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368571, 'Ergotamine', 'Bisoprolol', 'Moderate', 'Several case reports have suggested that beta-blockers may potentiate the vasoconstrictive action of ergot alkaloids. The exact mechanism of interaction is unknown, but may involve blockade of beta-2-mediated (i.e., sympathetic) vasodilatation. In addition, beta-1 blockade reduces cardiac output, which can diminish blood flow and exacerbate ergot-induced vasospasm.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary. Patients should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368572, 'Ertugliflozin', 'Bisoprolol', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368573, 'Etacrynic acid', 'Bisoprolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368574, 'Ethchlorvynol', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368575, 'Ethiodized oil', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368576, 'Etodolac', 'Bisoprolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368577, 'Felodipine', 'Bisoprolol', 'Moderate', 'Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'Metabolism, Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368578, 'Fenoldopam', 'Bisoprolol', 'Moderate', 'The use of fenoldopam in combination with beta-blockers has not been studied. Theoretically, beta-blockers may potentiate the risk of severe, symptomatic hypotension by inhibiting the sympathetic reflex response to fenoldopam-induced blood pressure decreases.', NULL, 'Concomitant use of fenoldopam with beta-blockers should be avoided if possible.', NULL, 'Concomitant use of fenoldopam with beta-blockers should be avoided if possible.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368579, 'Fenoprofen', 'Bisoprolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368580, 'Fingolimod', 'Bisoprolol', 'Major', 'The risk of severe bradycardia and atrioventricular (AV) block may be increased during initiation of fingolimod treatment in patients receiving other drugs that slow heart rate or AV conduction such as beta-blockers, certain calcium channel blockers (e.g., diltiazem, verapamil), and digitalis. Fingolimod can cause a decrease in heart rate during initiation of therapy that is apparent within an hour of the first dose and maximal at approximately 6 hours postdose in most cases, but occasionally up to 20 hours after the first dose.', NULL, 'Fingolimod has not been adequately studied in patients receiving beta-blockers, calcium channel blockers, or digitalis.', NULL, 'Fingolimod has not been adequately studied in patients receiving beta-blockers, calcium channel blockers, or digitalis. The possibility of switching to alternative agents that do not slow heart rate or AV conduction should be evaluated by the physician before initiating fingolimod. In patients who cannot switch, overnight continuous ECG monitoring after the first dose is recommended in accordance with the product labeling. The same precautions are applicable if, after the first month of treatment, fingolimod is discontinued for more than two weeks and then restarted, since the effects on heart rate and AV conduction may recur on reintroduction of fingolimod. Within the first 2 weeks of treatment, first-dose procedures are also recommended after interruption of one day or more; during week 3 and 4 of treatment, first-dose procedures are recommended after treatment interruption of more than 7 days. The first dose should always be administered in a setting where resources to appropriately manage symptomatic bradycardia are available.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368581, 'Flecainide', 'Bisoprolol', 'Moderate', 'Beta-blockers and flecainide may have additive negative inotropic effects. Areas under the curve were increased for both drugs and negative inotropic effects occurred when flecainide and propranolol were given to normal subjects. A case of bradycardia, atrioventricular block and cardiac arrest has been reported after sotalol was added to flecainide.', NULL, 'Careful monitoring of the patient''s hemodynamic status is recommended during concomitant administration.', NULL, 'Careful monitoring of the patient''s hemodynamic status is recommended during concomitant administration. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Patients should be advised to promptly report symptoms such as dizziness, slow or irregular heartbeats, syncope, or palpitations.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368582, 'Fludrocortisone', 'Bisoprolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368583, 'Fluphenazine', 'Bisoprolol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368584, 'Flurazepam', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368585, 'Flurbiprofen', 'Bisoprolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368586, 'Gadodiamide', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368587, 'Gadoteric acid', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368588, 'Gadoteridol', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368589, 'Gadoversetamide', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368590, 'Gadoxetic acid', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat. The mechanism is unknown. Theoretically, beta-blocker ophthalmic solutions may also interact, as they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368591, 'Garlic', 'Bisoprolol', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368592, 'Glimepiride', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368593, 'Glipizide', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368594, 'Glucagon', 'Bisoprolol', 'Minor', 'Beta-blockers may blunt the hyperglycemic reaction to glucagon by interfering with beta-adrenergic-mediated hyperglycemic counter-regulatory mechanisms.', NULL, '-', NULL, '-', 'Antagonism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368595, 'Glyburide', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368596, 'Glycopyrronium', 'Bisoprolol', 'Moderate', 'Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', 'Synergism, Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368597, 'Guanadrel', 'Bisoprolol', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368598, 'Guanethidine', 'Bisoprolol', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368599, 'Guanfacine', 'Bisoprolol', 'Moderate', 'Use of central alpha-2 adrenergic agonists, such as clonidine or guanfacine, with beta-blockers may have synergistic pharmacodynamic effects resulting in AV block, bradycardia, and hypotension. In addition, sinus node dysfunction may also be enhanced. Abrupt withdrawal of an alpha-2 agonist or both the alpha-2 agonist and the beta-blocker may also result in rebound hypertensive effects. The proposed mechanism is related to increased catecholamine release after alpha-2 agonist withdrawal which, when combined with concurrent beta-blockade, results in unopposed vasoconstriction.', NULL, 'Until more information is available, caution and close monitoring of blood pressure are recommended for patients receiving guanfacine with a beta-blocker.', NULL, 'Until more information is available, caution and close monitoring of blood pressure are recommended for patients receiving guanfacine with a beta-blocker. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some patients. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, headaches, or reduced or irregular heart rate.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368600, 'Halazepam', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368601, 'Haloperidol', 'Bisoprolol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368602, 'Diamorphine', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368603, 'Hydroflumethiazide', 'Bisoprolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368604, 'Hydromorphone', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368605, 'Hydroxyzine', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368606, 'Iloperidone', 'Bisoprolol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368607, 'Iloprost', 'Bisoprolol', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368608, 'Imipramine', 'Bisoprolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368609, 'Indacaterol', 'Bisoprolol', 'Moderate', 'Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.', NULL, 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.', NULL, 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368610, 'Indapamide', 'Bisoprolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368611, 'Indomethacin', 'Bisoprolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368612, 'Insulin human', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368613, 'Insulin aspart (aspart)', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368614, 'Insulin aspart (aspart protamine)', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368615, 'Insulin degludec', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368616, 'Insulin detemir', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368617, 'Insulin glargine', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368618, 'Insulin glulisine', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368619, 'Insulin human (inhalation, rapid acting)', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368620, 'Insulin human (isophane)', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368621, 'Insulin lispro', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368622, 'Insulin lispro (protamine)', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368623, 'Insulin human (regular)', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368624, 'Insulin human (zinc)', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368625, 'Insulin human (zinc extended)', 'Bisoprolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368626, 'Iodipamide', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368627, 'Iodixanol', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368628, 'Iohexol', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368629, 'Iopamidol', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368630, 'Iopanoic acid', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368631, 'Iopromide', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368632, 'Iothalamic acid', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368633, 'Ioversol', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368634, 'Ioxilan', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368635, 'Iopodic acid', 'Bisoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368636, 'Isocarboxazid', 'Bisoprolol', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368637, 'Isoetharine', 'Bisoprolol', 'Moderate', 'Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.', NULL, 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.', NULL, 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368638, 'Isoprenaline', 'Bisoprolol', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368639, 'Isradipine', 'Bisoprolol', 'Moderate', 'Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'Metabolism, Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368640, 'Ivabradine', 'Bisoprolol', 'Moderate', 'Coadministration of ivabradine with other drugs that can slow the heart rate such as beta-blockers, calcium channel blockers, and digitalis may increase the risk of excessive bradycardia or other conduction disturbances. Non-cardiac drugs that may also cause bradycardia include atazanavir, fingolimod, lacosamide, lithium, mefloquine, succinylcholine, thalidomide, H2-receptor antagonists, tricyclic antidepressants, and anticholinesterase or cholinergic agents.', NULL, 'Caution is advised when ivabradine is prescribed with other bradycardic drugs.', NULL, 'Caution is advised when ivabradine is prescribed with other bradycardic drugs. Heart rate should be closely monitored, and the dosage of ivabradine adjusted accordingly. Patients should be advised to report significant decreases in heart rate or symptoms such as dizziness, lightheadedness, fatigue, and hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368641, 'Bisoprolol', 'Kaolin', 'Minor', 'Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368642, 'Bisoprolol', 'Ketoprofen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368643, 'Bisoprolol', 'Lacosamide', 'Moderate', 'Lacosamide has been shown to prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, digoxin, atazanavir, mefloquine) may result in elevated risk of conduction disturbances and atrioventricular block.', NULL, 'Caution is advised if lacosamide is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.', NULL, 'Caution is advised if lacosamide is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.g., marked first-degree AV block, second-degree or higher AV block and sick sinus syndrome without pacemaker) or severe cardiac disease such as myocardial ischemia or heart failure. An ECG should be obtained in these patients before initiating lacosamide and after titration to steady-state.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368644, 'Bisoprolol', 'Lanreotide', 'Moderate', 'Somatostatin analogs (e.g., octreotide, lanreotide) can decrease heart rate and may potentiate the bradycardic effects of drugs like beta-blockers, calcium channel blockers, digitalis glycosides, and certain antiarrhythmic agents (e.g., class I antiarrhythmics, adenosine, amiodarone).', NULL, 'Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers.', NULL, 'Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers. Heart rate and blood pressure should be monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368645, 'Bisoprolol', 'Lanthanum carbonate', 'Moderate', 'INTERVAL: Theoretically, lanthanum carbonate may chelate with certain drugs in the gastrointestinal tract, resulting in reduced oral bioavailability of those drugs during coadministration.', NULL, 'To minimize the potential for interaction, drugs that are known to interact with antacids (e.', NULL, 'To minimize the potential for interaction, drugs that are known to interact with antacids (e.g., ACE inhibitors, beta blockers, bisphosphonates, coumarin derivatives, digitalis glycosides, fluoroquinolones, iron, phenytoin, rifampin, tetracyclines, thyroid preparations, valproic acid) should not be taken within 2 hours of administration of lanthanum carbonate according to the product labeling.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368646, 'Bisoprolol', 'Lasmiditan', 'Moderate', 'Coadministration of lasmiditan and agents that lower heart rate may increase the risk of bradycardia.', NULL, 'Caution is advised during coadministration of lasmiditan and agents that lower heart rate if the estimated decrease in heart rate may present a clinical risk.', NULL, 'Caution is advised during coadministration of lasmiditan and agents that lower heart rate if the estimated decrease in heart rate may present a clinical risk. Consider monitoring heart rate in patients for whom the estimated decrease in heart rate may not be tolerated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368647, 'Bisoprolol', 'Levosalbutamol', 'Moderate', 'Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.', NULL, 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.', NULL, 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368648, 'Bisoprolol', 'Levamlodipine', 'Moderate', 'Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'Metabolism, Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368649, 'Bisoprolol', 'Levobetaxolol (ophthalmic)', 'Moderate', 'Ophthalmic beta blocker solutions are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Additive effects of beta blockade may occur in patients receiving both oral and ophthalmic beta blocking agents.', NULL, 'Blood pressure and intraocular pressure monitoring is recommended during concurrent use.', NULL, 'Blood pressure and intraocular pressure monitoring is recommended during concurrent use. Patients should be advised to notify their physician if they experience a slow pulse, irregular heartbeat, dizziness, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368650, 'Bisoprolol', 'Levobunolol (ophthalmic)', 'Moderate', 'Ophthalmic beta blocker solutions are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Additive effects of beta blockade may occur in patients receiving both oral and ophthalmic beta blocking agents.', NULL, 'Blood pressure and intraocular pressure monitoring is recommended during concurrent use.', NULL, 'Blood pressure and intraocular pressure monitoring is recommended during concurrent use. Patients should be advised to notify their physician if they experience a slow pulse, irregular heartbeat, dizziness, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368651, 'Bisoprolol', 'Levodopa', 'Moderate', 'The hypotensive effects of levodopa and antihypertensive agents may be additive. Postural hypotension may occur.', NULL, 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', NULL, 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Dose adjustments of the antihypertensive agent may be required. Patients should be advised to notify their physician if they experience dizziness or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368652, 'Bisoprolol', 'Levothyroxine', 'Minor', 'Thyroid hormone therapy may reverse decreased hepatic blood flow associated with hypothyroidism. Increased hepatic metabolism and decreased serum levels of some beta-blockers may result. Data are available for propranolol only. No special precautions are necessary. When hypothyroidism is converted to a euthyroid state, a decrease in beta-blocking effectiveness is possible.', NULL, '-', NULL, '-', 'Others', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368653, 'Bisoprolol', 'Licorice', 'Moderate', 'Licorice use has been associated with hypertension and may antagonize the effects of antihypertensive agents. Glycyrrhizic acid, a component of licorice, is hydrolyzed in the intestine to a metabolite (glycyrrhetinic acid) that causes mineralocorticoid and renin-suppressing effects.', NULL, 'Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products.', NULL, 'Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products. Even relatively moderate doses of licorice may be problematic in susceptible patients when ingested regularly for prolonged periods.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368654, 'Bisoprolol', 'Linezolid', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368655, 'Bisoprolol', 'Liothyronine', 'Minor', 'Thyroid hormone therapy may reverse decreased hepatic blood flow associated with hypothyroidism. Increased hepatic metabolism and decreased serum levels of some beta-blockers may result. Data are available for propranolol only. No special precautions are necessary. When hypothyroidism is converted to a euthyroid state, a decrease in beta-blocking effectiveness is possible.', NULL, '-', NULL, '-', 'Others', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368656, 'Bisoprolol', 'Liotrix', 'Minor', 'Thyroid hormone therapy may reverse decreased hepatic blood flow associated with hypothyroidism. Increased hepatic metabolism and decreased serum levels of some beta-blockers may result. Data are available for propranolol only. No special precautions are necessary. When hypothyroidism is converted to a euthyroid state, a decrease in beta-blocking effectiveness is possible.', NULL, '-', NULL, '-', 'Others', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368657, 'Bisoprolol', 'Lithium carbonate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368658, 'Bisoprolol', 'Lofexidine', 'Moderate', 'The hypotensive effects of lofexidine and antihypertensive agents may be additive. Postural hypotension may occur.', NULL, 'Hemodynamic responses should be monitored during coadministration of lofexidine with antihypertensive agents, especially during the first few weeks of therapy.', NULL, 'Hemodynamic responses should be monitored during coadministration of lofexidine with antihypertensive agents, especially during the first few weeks of therapy.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368659, 'Bisoprolol', 'Lorazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368660, 'Bisoprolol', 'Loxapine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368661, 'Bisoprolol', 'Lumateperone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368662, 'Bisoprolol', 'Lurasidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368663, 'Bisoprolol', 'Magaldrate', 'Minor', 'Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368664, 'Bisoprolol', 'Magnesium carbonate', 'Minor', 'Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368665, 'Bisoprolol', 'Magnesium hydroxide', 'Minor', 'Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368666, 'Bisoprolol', 'Magnesium oxide', 'Minor', 'Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.', NULL, '-', NULL, '-', 'Absorption', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368667, 'Bisoprolol', 'Maprotiline', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368668, 'Bisoprolol', 'Maraviroc', 'Moderate', 'Maraviroc may potentiate the hypotensive effect of some medications.', NULL, 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure.', NULL, 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368669, 'Bisoprolol', 'Meclofenamic acid', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368670, 'Bisoprolol', 'Mefenamic acid', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368671, 'Bisoprolol', 'Mefloquine', 'Moderate', 'Mefloquine is a myocardial depressant and can cause ECG abnormalities. Theoretically, coadministration with other agents that can affect cardiac conduction (e.g., antiarrhythmic agents, beta blockers, calcium channel blockers, certain antihistamines, tricyclic antidepressants, phenothiazines, some neuroleptics) may result in additive effects and increased risk of ventricular arrhythmias including ventricular tachycardia and torsade de pointes.', NULL, 'Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction.', NULL, 'Caution and clinical monitoring are recommended if mefloquine is used in combination with other drugs that can prolong the QT interval or otherwise affect cardiac conduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes or other arrhythmia such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368672, 'Bisoprolol', 'Meloxicam', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368673, 'Bisoprolol', 'Mepenzolate', 'Moderate', 'Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', 'Synergism, Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368674, 'Bisoprolol', 'Meperidine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368675, 'Bisoprolol', 'Mephentermine', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.', NULL, 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368676, 'Bisoprolol', 'Meprobamate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368677, 'Bisoprolol', 'Mesoridazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368678, 'Bisoprolol', 'Orciprenaline', 'Moderate', 'Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.', NULL, 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.', NULL, 'Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368679, 'Bisoprolol', 'Metaraminol', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.', NULL, 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368680, 'Bisoprolol', 'Metaxalone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368681, 'Bisoprolol', 'Methacholine', 'Major', 'Patients who are concurrently receiving beta blockers may have exaggerated or prolonged responses (i.e., bronchoconstriction) to methacholine challenge and may not respond readily to treatment. Beta-2-adrenergic blockade increases airway resistance. Ophthalmically applied beta blockers undergo some systemic absorption and potentially may also interact.', NULL, 'Administration of methacholine to a patient on any beta blocker therapy is considered contraindicated.', NULL, 'Administration of methacholine to a patient on any beta blocker therapy is considered contraindicated.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368682, 'Bisoprolol', 'Methadone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368683, 'Bisoprolol', 'Methdilazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368684, 'Bisoprolol', 'Methocarbamol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368685, 'Bisoprolol', 'Methotrimeprazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368686, 'Bisoprolol', 'Methoxyflurane', 'Moderate', 'The antihypertensive effects of methoxyflurane and beta blockers may be additive. The combination may cause profound hypotension. Older anesthetics such as methoxyflurane have more severe circulatory depressant effects in the presence of beta-blockade.', NULL, 'It is currently recommended that beta blocker therapy not be routinely withdrawn prior to surgery.', NULL, 'It is currently recommended that beta blocker therapy not be routinely withdrawn prior to surgery. However, in general, patients taking beta blockers should not be anaesthetized with methoxyflurane. Instead, an anesthetic with minimal negative inotropic activity may be considered. If methoxyflurane must be used, beta blocker therapy should be withdrawn gradually and generally completed 24 to 48 hours before anesthesia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368687, 'Bisoprolol', 'Methyldopa', 'Moderate', 'Centrally acting antihypertensive agents and beta-blockers may have synergistic pharmacodynamic effects resulting in marked AV block, bradycardia, hypotension, and worsening of heart failure. In addition, potentiation of the hypertensive rebound associated with abrupt withdrawal of methyldopa and the beta blocker may occur.', NULL, 'Caution and monitoring of the patient''s hemodynamic status are recommended during coadministration or withdrawal of these drugs.', NULL, 'Caution and monitoring of the patient''s hemodynamic status are recommended during coadministration or withdrawal of these drugs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368688, 'Bisoprolol', 'Methylergometrine', 'Moderate', 'Several case reports have suggested that beta-blockers may potentiate the vasoconstrictive action of ergot alkaloids. The exact mechanism of interaction is unknown, but may involve blockade of beta-2-mediated (i.e., sympathetic) vasodilatation. In addition, beta-1 blockade reduces cardiac output, which can diminish blood flow and exacerbate ergot-induced vasospasm.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary. Patients should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368689, 'Bisoprolol', 'Methylprednisolone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368690, 'Bisoprolol', 'Methysergide', 'Moderate', 'Several case reports have suggested that beta-blockers may potentiate the vasoconstrictive action of ergot alkaloids. The exact mechanism of interaction is unknown, but may involve blockade of beta-2-mediated (i.e., sympathetic) vasodilatation. In addition, beta-1 blockade reduces cardiac output, which can diminish blood flow and exacerbate ergot-induced vasospasm.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary. Patients should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368691, 'Bisoprolol', 'Metipranolol (ophthalmic)', 'Moderate', 'Ophthalmic beta blocker solutions are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Additive effects of beta blockade may occur in patients receiving both oral and ophthalmic beta blocking agents.', NULL, 'Blood pressure and intraocular pressure monitoring is recommended during concurrent use.', NULL, 'Blood pressure and intraocular pressure monitoring is recommended during concurrent use. Patients should be advised to notify their physician if they experience a slow pulse, irregular heartbeat, dizziness, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368692, 'Bisoprolol', 'Metocurine', 'Moderate', 'Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1368693, 'Bisoprolol', 'Metolazone', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
